Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07265466
PHASE1

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Sponsor: Onconic Therapeutics Inc.

View on ClinicalTrials.gov

Summary

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Official title: A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban in Healthy Volunteers.

Key Details

Gender

All

Age Range

19 Years - 64 Years

Study Type

INTERVENTIONAL

Enrollment

96

Start Date

2025-11-17

Completion Date

2026-03-30

Last Updated

2025-12-04

Healthy Volunteers

Yes

Interventions

DRUG

JP-1366 and clopidogrel

A randomized, open label, multiple-dosing, 6-sequence, 3-period, 3-treatment, crossover design

DRUG

JP-1366 and aspirin

An open-label, multiple-dosing, fixed sequence, 3-period design

DRUG

JP-1366 and atorvastatin

An open-label, multiple-dosing, fixed sequence, 3-period design Period 1: Atorvastatin

DRUG

JP-1366 and apixaban

An open-label, multiple-dosing, fixed sequence, 3-period design

Locations (1)

Cha University Bundang Medical Center

Seongnam-si, Gyeonggi-do, South Korea